Lv7
4930 积分 2021-11-18 加入
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
2天前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
2天前
已完结
KRASG12C inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path
2天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
8天前
已关闭
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
14天前
已完结
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
16天前
已完结
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
23天前
已完结
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
1个月前
已关闭
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
1个月前
已完结
皖公网安备34019202002308
